The absence of final fourth-quarter and full-year earnings figures doesn’t stop Perrigo Co. PLC from offering plenty of information on its turnaround plans and its board shakeup nor deter analysts from noting concerns about the firm’s outlook.
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
The firm is reducing its non-production workforce by 750, a decision made after three representatives of disgruntled investor Starboard Value joined its board. Perrigo charts a course of recovery for its struggling international consumer health business, but some analysts are convinced it took a wrong turn with its 2015 investment in European OTC drug and nutritional product businesses and brands.
More from Europe
More from Geography
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
TikTok dietary supplement sales in Thailand grew by an astonishing 635% in 2024, while sales via Vietnam's and Malaysia's traditional e-commerce platforms increased by a still impressive 73% and 83% respectively.
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.